*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>A fixed-dose combination of <strong>Abacavir</strong>, <strong>Dolutegravir</strong>, and <strong>Lamivudine</strong> is an antiretroviral therapy for HIV-1. It integrates nucleoside reverse transcriptase inhibitors with an integrase strand transfer inhibitor.</p>
<h3>Application</h3>
<ul>
<li><strong>HIV Management:</strong> First-line treatment for adults and adolescents.</li>
<li><strong>Clinical Trials:</strong> Used in efficacy studies for viral suppression.</li>
<li><strong>Pharmaceutical Manufacturing:</strong> Bulk API sourcing for tablet formulation.</li>
</ul>
<h3>Precautions</h3>
<p>Screening for HLA-B*5701 allele is mandatory to prevent hypersensitivity. Store below 25°C in dry conditions. Contraindicated in patients with severe hepatic impairment or known hypersensitivity to components.</p>